Trial · NCT06563817
The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage
NCT06563817, Phase 2, Unknown, Beijing Tiantan Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage. Trials, record NCT06563817. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06563817
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage
- NCT number
- NCT06563817
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 53 participants, estimated
- Lead sponsor
- Beijing Tiantan Hospital
- Conditions
- Communicating Hydrocephalus, Cerebral Intraventricular Hemorrhage, Secondary Normal Pressure Hydrocephalus, Post Hemorrhagic Hydrocephalus
- Interventions
- Rapamycin
- First posted
- 2024-08-21
- Last updated
- 2024-08-21
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The objective remission rate of rapamycin for 4 weeks in the treatment of communicating hydrocephalus secondary to intraventricular hemorrhage is evaluated using the Idiopathic Normal Pressure Hydrocephalus Grading Scale (IPNHGS). | From the commencement of treatment to 4 weeks | Disease relief: Improvement of \>1 point on the Idiopathic Normal Pressure Hydrocephalus Grading Scale (iPNHGS) in patients after four weeks of rapamycin treatment compared to pre-treatment. Objective remission rate: The ratio of the number of patients who have achieved disease remission to the total number of patients enrolled in the study. |
| Secondary | Assessment of the incidence and severity of adverse events, serious adverse events, and other safety parameters (e.g., abnormal laboratory results) based on CTCAE V5.0 | From the commencement of treatment to 12 weeks after discontinuation of dosing | All events are determined based on CTCAE V5.0 |
| Secondary | The objective remission rate of rapamycin treatment of communicating hydrocephalus secondary to intraventricular hemorrhage is evaluated using the Idiopathic Normal Pressure Hydrocephalus Grading Scale (IPNHGS). | From the commencement of treatment to 2 weeks of dosing and 12 weeks after discontinuation of dosing | Disease relief: Improvement of \>1 point on the Idiopathic Normal Pressure Hydrocephalus Grading Scale (iPNHGS) in patients after four weeks of rapamycin treatment compared to pre-treatment. Objective remission rate: The ratio of the number of patients who have achieved disease remission to the total number of patients enrolled in the study. |
| Secondary | The objective remission rates of 3 clinical domains is evaluated using the Idiopathic Normal Pressure Hydrocephalus Grading Scale (IPNHGS). | From the commencement to 2 weeks of dosing, 4 weeks of dosing and 12 weeks after discontinuation of dosing | The 3 clinical domains include: gait, urinary incontinence, and cognition. For gait, positive outcome was defined that improvement of \>1 point in the gait section of iNPHGS; for urinary incontinence, a positive outcome was defined that improvement of \>1 point in the urinary section of iNPHGS; For cognition, positive outcome was defined that improvement of \>1 point in the cognition section of iNPHGS |
| Secondary | Changes in plasma biomarkers | From the commencement to 2 weeks of dosing, 4 weeks of dosing and 12 weeks after discontinuation of dosing | Change in plasma levels of TNF-α, IL-1β, IL-6, IL-10, IL-8 and IL-2R. |
| Secondary | Change in CSF biomarkers | From the commencement to 2 weeks of dosing, 4 weeks of dosing and 12 weeks after discontinuation of dosing | Change in plasma levels of TNF-α, IL-1β, IL-6, IL-10, IL-8 and IL-2R. |
| Secondary | Change in Euro-Quality of Life-5 dimension-5L (EQ-5D-5L) descriptive system | From the commencement to 2 weeks of dosing, 4 weeks of dosing and 12 weeks after discontinuation of dosing | Measured using EQ-5D-5L using the descriptive system. |
| Other | Screening of potential beneficiary population | From the commencement of treatment to 4 weeks | Identification of a patient population with secondary communicating hydrocephalus after intraventricular hemorrhage that may benefit from rapamycin therapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 36803604 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06563817
GET https://conductscience.org/api/trials/v1/NCT06563817/registered